Thermidas’ thermal imaging method is the first in the world to receive CE approval for Class IIa medical devices

Thermidas Oy has achieved a groundbreaking milestone. Our thermal imaging method has become the first of its kind in the world to receive Class IIa medical device CE approval for our “Thermidas IRT-384 Tablet” and “Thermidas VistaClinic Analyzer” products.

Based on the latest clinical evaluation report, the product provides new insights into the analysis of diabetic foot ulcers, pressure injuries, vascular disorders, arthritis, skin cancer, and autonomic dysfunction in patients. These insights not only aid clinicians in making sound clinical decisions but may also empower patients with a greater awareness of their conditions, enabling them to actively participate in their own care.

This revolutionary technology offers a new paradigm in medical imaging, providing unprecedented accuracy, speed, and cost-efficiency. With 17 years of dedicated development and comprehensive clinical research, we have ensured the effectiveness and safety of our products.

Thermidas is the first company globally with CE marking for its thermal imaging product in Europe and FDA 510(k) clearance in the United States. This dual recognition positions us at the forefront of healthcare imaging technology, driving global advancements in medical practices.

We are now focused on commercializing this method and actively seeking distributors worldwide. Thermidas’ technology is already used in every university hospital in Finland, confirming its practical value and functionality.

Thermidas Oy is a Finnish company providing thermal imaging technology for healthcare. The company’s solutions enable fast and safe measurement of body surface temperature, which helps to detect abnormalities such as inflammation, circulatory problems or the risk of ulcers. Thermidas products are used in areas such as diabetic foot ulcer prevention, physiotherapy and nursing homes.